In recent years, combination therapies in type 2 diabetes (T2DM) are in focus, as a single anti-diabetic agent cannot correct all the pathophysiologic defects manifested in T2DM. Combination therapies exert different mechanisms of action, which provides the potential to complement their action and the properties to counter the undesired compensatory response. Combination therapies with sodium-glucose co-transporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors are particularly appealing and are expected to have glucose-lowering potential with other additive effects.
1 The combination therapy of DPP4 inhibitors and SGLT2 inhibitors have a synergistic pleiotropic benefit that could help in improving several cardio-renal outcomes. Also, this combination has been speculated to be nephroprotective as both the drug classes have shown a lowering in albumin excretion rates.…